RxDoctor Payments Data

Saramma Eappen, MD

Psychiatry · Burlington, NCNPI 1225397987

Payments from drug & device makers

$646in general payments, 2019–2025

Across 33 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Otsuka America Pharmaceutical, Inc.$151
  • Sunovion Pharmaceuticals Inc.$116
  • Neurocrine Biosciences, Inc.$33
  • E.r. Squibb & Sons, L.L.C.$27
  • Axsome Therapeutics, Inc.$25
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$61896%
  • Education$274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646 in reported general payments places this provider in the 65th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$21,548
Medicare patients
48
Services billed
2,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate30$100,749
RexultiBrexpiprazole34$57,850
VraylarCariprazine Hcl25$35,970
TrintellixVortioxetine Hydrobromide36$18,648
Varenicline Tartrate44$9,274
QuviviqDaridorexant Hcl17$8,338
BelsomraSuvorexant16$7,783
Lurasidone Hcl42$4,814
Duloxetine Hcl188$4,158
DayvigoLemborexant11$3,712
Venlafaxine Hcl ErVenlafaxine Hcl142$3,192
Vilazodone Hcl14$2,832
Buspirone Hcl148$2,672
Divalproex Sodium ErDivalproex Sodium84$2,623
Aripiprazole80$2,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$16$100,74930 claims
Otsuka America Pharmaceutical, Inc.Rexulti$151$57,85034 claims
AbbVieVraylar$240$35,97025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →